Autolus Therapeutics PLC - ESG Rating & Company Profile powered by AI
The Disclosure score includes seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Reduced Inequalities' and 'Life below Water'. Other companies in the rating industry group for Autolus Therapeutics PLC are shown below. This article contains a Q&A table for Autolus Therapeutics PLC.
Autolus Therapeutics PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 6.0, social score of 4.8 and governance score of 4.8.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 658 | Transchem Ltd | 5.3 | High |
| 658 | Zenith Healthcare Ltd | 5.3 | High |
| 687 | Autolus Therapeutics PLC | 5.2 | High |
| 687 | Cardiol Therapeutics Inc | 5.2 | High |
| 687 | Cell Source Inc | 5.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Autolus Therapeutics PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Autolus Therapeutics PLC report the average age of the workforce?
Sign up for free to unlockDoes Autolus Therapeutics PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Autolus Therapeutics PLC offer flexible work?
Sign up for free to unlockDoes Autolus Therapeutics PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Autolus Therapeutics PLC conduct supply chain audits?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Autolus Therapeutics PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose water use targets?
Sign up for free to unlockDoes Autolus Therapeutics PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Autolus Therapeutics PLC have a product recall in the last two years?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Autolus Therapeutics PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Autolus Therapeutics PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose parental leave metrics?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Autolus Therapeutics PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Autolus Therapeutics PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Autolus Therapeutics PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose its waste policy?
Sign up for free to unlockDoes Autolus Therapeutics PLC report according to TCFD requirements?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose energy use targets?
Sign up for free to unlockDoes Autolus Therapeutics PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Autolus Therapeutics PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Autolus Therapeutics PLC
These potential risks are based on the size, segment and geographies of the company.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.